Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedFeb 08, 2026
DataAggregated Company Financials
Companies15
  • 7D6.9%
  • 3M12.6%
  • 1Y24.8%
  • YTDn/a

In the last week, the Pharma industry is up 6.9%, with GSK up 17%. During this same period, the Allergy Therapeutics underperformed, falling 8.4%. This takes the industry's 12 month performance to a gain of 25%. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 08 Feb 2026UK£348.0bUK£89.3bUK£14.7b24x23.6x3.9x
Tue, 06 Jan 2026UK£319.2bUK£89.2bUK£14.6b21.8x21.9x3.6x
Thu, 04 Dec 2025UK£323.8bUK£89.8bUK£14.7b21.1x22.1x3.6x
Sat, 01 Nov 2025UK£302.8bUK£89.3bUK£13.9b20.7x21.7x3.4x
Mon, 29 Sep 2025UK£265.8bUK£87.8bUK£11.7b18.4x22.6x3x
Wed, 27 Aug 2025UK£281.7bUK£87.6bUK£11.7b21.7x24.1x3.2x
Fri, 25 Jul 2025UK£265.2bUK£86.4bUK£10.6b30.1x25x3.1x
Sun, 22 Jun 2025UK£259.3bUK£86.6bUK£10.6b25.9x24.4x3x
Tue, 20 May 2025UK£260.7bUK£86.9bUK£10.7b26.5x24.4x3x
Thu, 17 Apr 2025UK£254.7bUK£86.6bUK£9.6b26.9x26.5x2.9x
Sat, 15 Mar 2025UK£290.1bUK£87.7bUK£9.6b28.8x30.2x3.3x
Mon, 10 Feb 2025UK£280.9bUK£89.5bUK£9.5b30.1x29.4x3.1x
Wed, 08 Jan 2025UK£228.3bUK£75.6bUK£7.8b31.8x29.3x3x
Fri, 06 Dec 2024UK£226.8bUK£74.7bUK£7.7b32.1x29.5x3x
Sun, 03 Nov 2024UK£236.3bUK£72.6bUK£7.6b31.1x31.2x3.3x
Tue, 01 Oct 2024UK£249.2bUK£71.3bUK£8.9b30.4x27.9x3.5x
Thu, 29 Aug 2024UK£279.6bUK£71.9bUK£9.0b41.9x31.2x3.9x
Sat, 27 Jul 2024UK£259.8bUK£72.2bUK£9.6b34.8x27.2x3.6x
Mon, 24 Jun 2024UK£266.4bUK£71.7bUK£9.6b30.2x27.8x3.7x
Wed, 22 May 2024UK£271.2bUK£71.5bUK£9.6b33.9x28.3x3.8x
Fri, 19 Apr 2024UK£243.1bUK£71.4bUK£9.8b31.9x24.9x3.4x
Sun, 17 Mar 2024UK£236.0bUK£70.4bUK£9.7b32.3x24.3x3.4x
Tue, 13 Feb 2024UK£220.4bUK£69.7bUK£9.6b34.4x22.9x3.2x
Thu, 11 Jan 2024UK£244.6bUK£68.8bUK£10.7b36.5x22.9x3.6x
Sat, 09 Dec 2023UK£226.9bUK£69.4bUK£10.7b33.4x21.1x3.3x
Mon, 06 Nov 2023UK£229.8bUK£70.3bUK£11.0b53x20.9x3.3x
Wed, 04 Oct 2023UK£244.4bUK£70.9bUK£10.5b76.3x23.4x3.4x
Fri, 01 Sep 2023UK£236.3bUK£69.1bUK£10.2b53.5x23.2x3.4x
Sun, 30 Jul 2023UK£241.7bUK£68.1bUK£9.9b52.3x24.5x3.5x
Tue, 27 Jun 2023UK£245.7bUK£67.8bUK£7.9b55.5x31.2x3.6x
Thu, 25 May 2023UK£252.4bUK£68.8bUK£8.0b55.7x31.6x3.7x
Sat, 22 Apr 2023UK£262.0bUK£69.3bUK£6.9b63.2x38.2x3.8x
Mon, 20 Mar 2023UK£235.7bUK£70.1bUK£6.9b44.3x34x3.4x
Wed, 15 Feb 2023UK£251.2bUK£70.1bUK£7.4b40.9x34.2x3.6x
Price to Earnings Ratio

34.2x


Total Market Cap: UK£251.2bTotal Earnings: UK£7.4bTotal Revenue: UK£70.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 26.7x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 23.6x which is lower than its 3-year average PE of 26.7x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 8.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does U.K. Pharma compare with similar industries?

GB Market1.13%
Healthcare6.36%
Pharma6.88%
Pharma6.88%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GSK GSKUK£21.9817.1%
+UK£12.9b		52.3%PE15.4x
AZN AstraZenecaUK£141.043.7%
+UK£7.8b		21.6%PE31.7x
HLN HaleonUK£3.985.1%
+UK£1.7b		4.9%PE23.3x
HIK Hikma PharmaceuticalsUK£15.400.7%
+UK£24.4m		-32.6%PE12.5x
POLB Poolbeg PharmaUK£0.0464.5%
+UK£1.4m		-10.7%PB2.7x

Latest News

GSK
UK£21.98
GSK
7D
17.1%
1Y
52.3%
NFX
UK£0.0023
Nuformix
7D
21.1%
1Y
206.7%
FUM
UK£0.013
Futura Medical
7D
-3.4%
1Y
-90.5%
HCM
UK£2.14
HUTCHMED (China)
7D
-2.7%
1Y
1.4%
STX
UK£0.096
Shield Therapeutics
7D
-10.7%
1Y
220.0%

STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside

Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).
HIK
UK£15.40
Hikma Pharmaceuticals
7D
0.7%
1Y
-32.6%

HIK: Leadership Reset And New Guidance Will Support Earnings Outlook

Analysts have adjusted their price targets for Hikma Pharmaceuticals within a wide £1,600 to £2,400 range, reflecting differing views on management clarity, strategic direction, and available catalysts for the shares. Analyst Commentary Recent research on Hikma Pharmaceuticals shows a split between analysts who see upside potential and those who are more cautious, which helps explain the wide spread in price targets.
AZN
UK£141.04
AstraZeneca
7D
3.7%
1Y
21.6%

AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook

Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.
AGY
UK£0.11
Allergy Therapeutics
7D
-8.4%
1Y
71.9%
HLN
UK£3.98
Haleon
7D
5.1%
1Y
4.9%

HLN: Portfolio Execution And New Operating Model Will Support Re Rating

The average analyst price target for Haleon has edged up to £5.17 from £5.10, as analysts cite slightly higher margin assumptions, a modest reset to revenue growth expectations, and supportive recent rating changes and target increases from several firms across the Street. Analyst Commentary Recent Street research on Haleon has been active, with both bullish and more cautious voices weighing in.
TLM
UK£0.083
Talisman Metals
7D
26.9%
1Y
89.7%
ANCR
UK£2.80
Animalcare Group
7D
-1.1%
1Y
18.6%
EAH
UK£1.11
ECO Animal Health Group
7D
-1.8%
1Y
75.4%

Earnings Not Telling The Story For ECO Animal Health Group plc (LON:EAH) After Shares Rise 25%

Dec 04
Earnings Not Telling The Story For ECO Animal Health Group plc (LON:EAH) After Shares Rise 25%
POLB
UK£0.046
Poolbeg Pharma
7D
4.5%
1Y
-10.7%
SAR
UK£0.17
Sareum Holdings
7D
-2.9%
1Y
-8.1%
IMM
UK£0.064
ImmuPharma
7D
0.3%
1Y
39.3%